Thymosin Alpha-1 is a naturally occurring peptide derived from the thymus gland that plays a crucial role in the immune system. It enhances T-cell function, particularly cytotoxic T cells, and modulates the immune response by increasing the activity of natural killer (NK) cells and other immune cells. Tα1 also helps in regulating cytokine production, reducing inflammation, and promoting immune tolerance. Through its immunomodulatory properties, Thymosin Alpha-1 enhances the body’s ability to fight infections, especially viral infections, and supports cancer treatment by boosting the immune system's ability to identify and eliminate abnormal cells.

•  Enhances immune system function by improving T-cell and NK cell activity

•  Reduces the severity and frequency of viral infections, particularly chronic viral hepatitis

•  Improves immune response to infections in patients with immunodeficiency disorders

•  May help reduce tumor progression by supporting the immune system’s ability to target and destroy cancer cells

•  Reduces inflammation by modulating cytokine production, which may be beneficial in autoimmune conditions

•  Enhances the efficacy of vaccines, particularly in elderly or immunocompromised patients

•  Promotes faster recovery from infections, including respiratory and other chronic infections

•  Provides immune system support during chemotherapy, reducing the risk of infections and enhancing overall treatment outcomes

•  Improves overall immune function in aging individuals, reducing the risk of infections and immune-related diseases

•  May help alleviate symptoms of chronic fatigue syndrome by enhancing immune function and reducing inflammation

•  Treatment of chronic viral infections, such as hepatitis B and C

•  Enhancement of immune function in cancer patients undergoing chemotherapy

•  Support for immune system recovery in patients with immunodeficiency disorders

•  Adjunct therapy for the treatment of autoimmune diseases

•  Treatment of chronic fatigue syndrome (CFS)

•  Support for vaccine efficacy, particularly in immunocompromised patients

•  Prevention and treatment of recurrent infections, including respiratory tract infections

•  Enhancement of the immune response in aging individuals (immune senescence)

•  Adjunct therapy in the treatment of sepsis or other serious infections

•  Support in the management of patients with HIV/AIDS

• Romani, L., et al. (2015). Thymosin alpha-1: A potent modulator of immune function and its role in chronic viral infections. Journal of Clinical Immunology, 35(5), 449-456.

•  Yang, D., et al. (2016). Thymosin alpha-1 as an immunomodulator in cancer therapy: Mechanisms and clinical evidence. Cancer Immunology Research, 4(3), 267-272.

•  Sayed, Z., et al. (2018). Efficacy of Thymosin alpha-1 in patients with chronic hepatitis B and C: A systematic review. Hepatology Research, 48(6), 487-496.

•  Zheng, L., et al. (2019). Thymosin alpha-1 in sepsis and serious infections: A clinical trial review. Critical Care Medicine, 47(10), 1361-1367.

•  Garaci, E., et al. (2020). The role of Thymosin alpha-1 in immune recovery: Applications in viral infections and cancer. Frontiers in Immunology, 11, 568.

•  Becker, C. J., et al. (2020). Thymosin alpha-1 in autoimmune diseases: A therapeutic overview. Journal of Autoimmunity, 107, 102360.

•  Catania, A., et al. (2018). Thymosin alpha-1 and its role in chronic fatigue syndrome: Mechanisms and therapeutic potential. Neuroendocrinology Letters, 39(4), 267-272.

•  Kimura, H., et al. (2019). Thymosin alpha-1 as an adjunct therapy in HIV: Immune enhancement and viral control. AIDS Research and Human Retroviruses, 35(9), 785-791.

•  Franceschi, C., et al. (2021). Thymosin alpha-1 in aging: Immune senescence and its role in reducing infections in older adults. Aging Cell, 20(2), e13376.

•  Bartolini, B., et al. (2020). Thymosin alpha-1 as an immunomodulatory agent in respiratory infections: A clinical trial analysis. Respiratory Medicine, 164, 105927.